Novel compounds and therapeutic use thereof for protein kinase inhibition

A compound of formula I:

• wherein
• Y═NH, O, or S,
• R1=selected from following groups:
• wherein X═CH2, NH, S, or O,
• R8═—H, —NH2, —OH, —N(R4, R5), —C(R4R5)1-7NR6R7, —C(R4R5)1-7OR6, or —N(R4)NR5R6, wherein R4, R5, R6, R7═H, alkyls (C1-C6), cycloalkyls (C3-C8) with or without nuclear heteroatoms such as O, S, and N, aryls (either unsubstituted or substituted aromatics), or heteroaromatics (either unsubstituted or substituted heteroaromatics),
• R9, R10, R11, R12, and R13═H, alkyls (C1-C6), cycloalkyls (C3-C8) with or without nuclear heteroatoms such as O, S or N;
• aryls (either unsubstituted and substituted aromatics), or heteroaromatics (either unsubstituted or substituted heteroaromatics),
• R2, is selected from a group consisting of H, OH, NH2, OR14, NR14R15, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, and alkynyl,
• wherein R14, R15═H, alkyls (C1-C6), cycloalkyls (C3-C8) with or without nuclear heteroatoms such as O, S, N, aryls (either unsubstituted or substituted aromatics), or heteroaromatics (either unsubstituted or substituted heteroaromatics),
• and
• R3 is selected from a group consisting of H, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, and alkynyl. Specifically R3 is selected from the following groups:
• wherein R16, R17, and R18 are selected from following groups:
• H;
• heteroatom such as F, Cl, Br, I;
• alkyl(C1-C8);
• cycloalkyl (C3-C8) without or with substitutions, wherein a substitution is selected from the group consisting of alkyls (C1-C8), cycloalkyls (C3-C8), aryls, heteroaryls;
• —OR19;
• —SR19;
• —NR19R20;
• —S(O)R19;
• —S(O)2R19;
• —S(O)NR19R20;
• —C(O)NR19R20;
• —N(R19)C(O)R20;
• —N(R19)S(O)2R20;
• —N(R19)C(O)N(R20R21);
• N(R19)C(O)OR20;
• aryl with or without substitution, heteroaryl with or without substitution, aryalkyl with or without substitution, heterocyclyl with or without substitution, heteterocyclylalkyl with or without substitution;
• alkenyl with or without substitution, and alkynyl with or without substitution;
• where R19, R20, and R21 are independently chosen from H, alkyl (C1-C8), cycloalkyls (C3-C8), aryl with or without substitution, alkylaryl with or without substitutions, heteroaryl with or without substitution,
• or R16, R17, and R21 can be part of a fused ring containing 0-3 heteroatoms selected from N, O, and S.